ATOSSA THERAPEUTICS INC. - COMMON STOCK
0.7167
12-March-25 16:45:00
15 minutes delayed
Stocks
-0.0241
-3.25%
Today's range
0.7000 - 0.7490
ISIN
N/A
Source
NASDAQ
-
09 Apr 2024 11:59:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
05 Apr 2024 09:58:53 By NetDania Notify
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
04 Apr 2024 11:38:29 By NetDania Notify
-
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
01 Apr 2024 16:00:00 By Nasdaq GlobeNewswire
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
01 Apr 2024 12:27:21 By NetDania Notify
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
28 Mar 2024 10:08:00 By NetDania Notify
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
26 Mar 2024 09:45:03 By NetDania Notify
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
25 Mar 2024 10:40:51 By NetDania Notify
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
20 Mar 2024 09:45:01 By NetDania Notify
-
NetDania - New 12 months High: ATOSSA THERAPEUTICS INC. - COMMON STOCK
19 Mar 2024 10:49:14 By NetDania Notify
-
19 Mar 2024 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
18 Mar 2024 08:30:00 By Nasdaq GlobeNewswire
-
12 Mar 2024 08:30:00 By Nasdaq GlobeNewswire
-
06 Mar 2024 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
22 Feb 2024 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
07 Feb 2024 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Issues Letter to Shareholders
09 Jan 2024 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
04 Dec 2023 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial
20 Nov 2023 08:30:00 By Nasdaq GlobeNewswire
-
Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
13 Nov 2023 09:00:00 By Nasdaq GlobeNewswire